Thera-SAbDab

BENRALIZUMAB

>   Structural Summary
TherapeuticBenralizumab
TargetIL5RA
Heavy ChainEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYVIHWVRQRPGQGLAWMGYINPYNDGTKYNERFKGKVTITSDRSTSTVYMELSSLRSEDTAVYLCGREGIRYYGLLGDYWGQGTLVTVSS
Light ChainDIQMTQSPSSLSASVGDRVTITCGTSEDIINYLNWYQQKPGKAPKLLIYHTSRLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGYTLPYTFGQGTKVEIK
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (June '19)Approved
Estimated Status (June '19)Active
Recorded Developmental TechnologyPOTELLIGENT Technology
INN Year Proposed2009
INN Year Recommended2010
Companies InvolvedAstraZeneca, Cincinnati Children's Hospital Medical Center, Kyowa Hakko, Kyowa Hakko Kirin, McMaster University, MedImmune, National Jewish Medical and Research Center, BioWa
Conditions ApprovedAsthma
Conditions ActiveChronic obstructive pulmonary disease, Nasal polyps, Atopic dermatitis, Churg-Strauss syndrome, Hypereosinophilic syndrome, Rhinosinusitis, Eosinophilic gastroenteritis, Skin disorders
Conditions Discontinuedna
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]